When Allergan transferred six Restasis patents to the Saint Regis Mohawk tribe in 2017 in a bid to shield the dry-eye treatment from generic competition, it was widely maligned by everyone from industry insiders to tech giants like Microsoft. And in July,
By most measures Allergan has not had the most successful of years and one measure, in particular, is usually indicative of a company’s performance, share price.